•
Mar 31, 2021

CryoPort Q1 2021 Earnings Report

Cryoport's revenue grew to a record $53.3 million, driven by the Biopharma/Pharma market and recent acquisitions.

Key Takeaways

Cryoport reported a strong first quarter with record revenue of $53.3 million, driven by growth in all operating units and contributions from recent acquisitions. The Biopharma/Pharma market represented approximately 80% of total revenue. The company supported a record 543 regenerative medicine clinical trials.

Cryoport's revenue grew to a record $53.3 million.

All business units reported record revenue and strong sequential growth.

The Biopharma/Pharma market represented approximately 80% of total revenue.

Cryoport supported a record 543 regenerative medicine clinical trials.

Total Revenue
$53.3M
Previous year: $9.77M
+445.2%
EPS
-$0.13
Previous year: -$0.11
+18.2%
Gross Profit
$24.6M
Previous year: $5.26M
+366.9%
Cash and Equivalents
$85.5M
Previous year: $50.6M
+68.9%
Free Cash Flow
-$8.8M
Previous year: $463K
-2001.1%
Total Assets
$820M
Previous year: $140M
+485.0%

CryoPort

CryoPort